Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: moby_dick who wrote (19305)	3/10/1999 5:53:00 PM
From: Anthony@Pacific	Read Replies (3) \| Respond to of 122087

THIS NEWS WAS RELEASED ON THE MERCK NEWS WIRE YESTERDAY SYMBOL MRK>> It is worth verifying ..but unlikely....that this guy knows what he is talking about DJN ImClone/Merck KGaA -2:Payment Contingent On FDA OK For Trial Mar 9 1999 6:31 NEW YORK (Dow Jones)--ImClone Systems Inc. (IMCL) said it will receive a $5 million milestone payment from Merck KGaA, its corporate partner in the development of C225. In a press release Tuesday, ImClone said the payment is based on the completion of a successful meeting with the Food and Drug Administration allowing ImClone to initiate a Phase III clinical trial to treat patients with advanced squamous cell head and neck cancer using its cancer therapeutic, C225. C225 is a monoclonal antibody that inhibits activity of epidermal growth factor receptor associated with cancer cell growth in a number of solid tumors. ImClone said the Phase III trial will evaluate the effect of C225 in combination with radiation in about 416 patients with advanced squamous cell head and neck cancer. As reported in December, ImClone and Merck signed an agreement for the development and commercialization of ImClone's C225 product. ImClone Systems is a biopharmaceutical company. Merck KGaA, Darmstadt, Germany, operates in the pharmaceuticals, laboratory and specialty chemicals business. (MORE) DOW JONES NEWS 03-09-99 XXXXXXXXXXXXXXX HEADLINES<---See Release No. 18 XXXXXXXXXXXXXXX Headlines for: MERCK & CO., INC. (MRK) WIRE TIME Page 1 1 BN 14:32 DuPont Plans Alliances, New Stock for Life Sciences (Update6) 2 BN 13:46 Genentech Shares Hit Record High on Release of Heart Drug Data 3 BN 13:25 DuPont Plans Alliances, New Stock for Life Sciences (Update5) 4 BN 13:19 Boehringer's Oral Clot Preventing Drug Indicated Safe in Study 5 BN 13:09 DuPont Plans Alliances, New Stock for Life Sciences (Update4) 6 BN 11:40 DuPont Plans Alliance, New Stock for Life Sciences (Update3) 7 •BN 8:58 DuPont Plans Alliance, New Stock for Life Sciences (Update2) 8 DJN 6:51 Merck & Co (MRK) Block: 271,500 Shares At 82 1/2 9 DJN 5:05 =WEEKDAY TRADER: Is Merck's Medicine Chest Getting Bare? 10 DJN 3/09 Merck Study Boosts Rival Warner Lambert's Cholesterol Drug 11 DJN 3/09 WEEKDAY TRADER: Is Merck's Medicine Chest Getting Bare? -2: 12 DJN 3/09 WEEKDAY TRADER: Is Merck's Medicine Chest Getting Bare? 13 BN 3/09 Genentech's, Bristol's Heart Drugs See Strong Results (Update1) 14 DJN 3/09 ImClone/Merck KGaA -3: ImClone Meeting With FDA Successful 15 BN 3/09 Genentech, Bristol's New Clot-Busters See Strong Trial Results 16 DJN 3/09 Amer Biogenetic Names Glenna Crooks Director; Boosts Bd To 8 17 DJN 3/09 Merck & Co (MRK) Block: 149,600 Shares At 82 7/16 18 DJN 3/09 ImClone/Merck KGaA -2:Payment Contingent On FDA OK For Trial 19 DJN 3/09 =Prescription Totals Keep Rising For Monsanto's Celebrex 20 PRN 3/09 AMERICAN BIOGENETIC SCIENCES APPOINTS FORMER MERCK SENIOR EXECUT To identify a newswire, type NTRB {wire} <GO>